Winship key to four new myeloma drugs in 2015

lonial patientThe U.S. Food and Drug Administration (FDA) approved elotuzumab as part of an innovative immune-based therapy treatment for patients with relapsed multiple myeloma. This is the third myeloma drug approved by the FDA within the last month and the fourth new myeloma treatment approved within the last year. All four new agents were tested in clinical trials at Winship Cancer Institute of Emory University.

Sagar Lonial, MD, chief medical officer of Winship, says the potential of elotuzumab can be seen in the overall response rate as well as the longer duration of progression-free survival.

“The Winship multiple myeloma team has shepherded several of these treatments from the beginning stages of testing through to their approval,” said Lonial. “It’s a great source of pride to know we were instrumental in the process that has led to many more treatment options for our patients.”

Read the full press release here.

cta-learn-blue

Tags: , , , ,